Pfizer buys Vicuron for $1.9B
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Pfizer |
Vicuron Pharmaceuticals |
$1.9B buyout |
The move hands Pfizer new anti-infectives for both hospital-based and community-acquired infections. |
|
ML Laboratories |
Quadrant Technologies |
£46.7 million acquisition |
The buyout gives ML Laboratories a big boost in the field of inhaled medicines. |
|
Clinical Data |
Genaissance Pharmaceuticals |
$56 million acquisition |
The buyout provides Clinical Data -- a diagnostic company -- with a leader in molecular testing. |
|
GNI Ltd. |
Shanghai Genomics |
Merger |
The combination marries GNI's clinical development programs with Shanghai Genomics' contract research abilities. |
|
Genentech |
Biogen Idec |
$408 million plant acquisition |
Biogen Idec is selling its California manufacturing facility as Tysabri's fate remains in limbo. |
|
Cephalon |
Cell Therapeutics |
Trisenox acquisition |
Cephalon adds an approved drug for hematologic malignancies. |
|
QVT Fund |
Biosynexus |
Acquisition |
The New York hedge fund acquires a portfolio of products for the prevention and treatment of infectious diseases. |
|
Fisher Scientific |
McKesson |
$60 million subsidiary buyout |
Fisher Scientific is buying the Bioservices division, which manages biological specimens and clinical trial materials. |